Basic Information | Post buying leads | Suppliers | Cas Database |
Name |
Chlorpromazine hydrochloride |
EINECS | 200-701-3 |
CAS No. | 69-09-0 | Density | 1.077 g/cm3 (15 C) |
PSA | 31.78000 | LogP | 5.76140 |
Solubility | >=10 g/100 mL at 24 °C | Melting Point |
192-196 °C |
Formula | C17H19ClN2S.HCl | Boiling Point | 450.1 °C at 760 mmHg |
Molecular Weight | 355.331 | Flash Point | 226 °C |
Transport Information | UN 2811 6.1/PG 1 | Appearance | creamy white crystalline powder |
Safety | 28-36/37-45 | Risk Codes | 25-26 |
Molecular Structure | Hazard Symbols | T+ | |
Synonyms |
10H-Phenothiazine-10-propanamine,2-chloro-N,N-dimethyl-, monohydrochloride (9CI);Phenothiazine,2-chloro-10-[3-(dimethylamino)propyl]-, monohydrochloride (8CI);2-Chloro-10-(3-dimethylaminopropyl)phenothiazine monohydrochloride;Aminazin monohydrochloride;Chloractil;Hebanil;Hibanil;Hibernal;Klorproman;Klorpromex;Largactil;Largaktyl;Marazine;Megatil;Norcozine;Promacid;Propaphen; |
Article Data | 3 |
2-chlorophenothiazine
3-(dimethylamino)propyl chloride hydrochloride
chlorpromazine hydrochloride
Conditions | Yield |
---|---|
With potassium hydroxide; Aliquat 336 at 80℃; for 1h; | 85% |
Conditions | Yield |
---|---|
In water Kinetics; deoxygenated solutions, 25.0-38.7°C, 0.1 to 1.0 M - H(1+); not isolated, detd. by stopped-flow UV/VIS spectroscopy; |
Conditions | Yield |
---|---|
With oxygen; nitrogen(II) oxide In acetonitrile for 2h; -20 deg C -> room temperature; | 100% |
With oxygen In acetonitrile for 2h; Product distribution; -20 deg C -> room temperature; aerial oxidation of various phenothiazines and related compounds catalysed by nitrogen oxides, possible mechanism, intermediate cation radicals; | 100% |
With ethanol; dihydrogen peroxide |
Conditions | Yield |
---|---|
In water E-2 M solns. were mixed; ppt. was filtered, thoroughly washed with distd. water, dried at room temp., elem. anal.; | 99.5% |
chlorpromazine hydrochloride
Conditions | Yield |
---|---|
In water E-2 M solns. were mixed; ppt. was filtered, thoroughly washed with distd. water, dried at room temp., elem. anal.; | 99.5% |
Conditions | Yield |
---|---|
In water E-2 M solns. were mixed; ppt. was filtered, thoroughly washed with distd. water, dried at room temp., elem. anal.; | 99.5% |
Conditions | Yield |
---|---|
Stage #1: chlorpromazine hydrochloride With sodium hydroxide In diethyl ether Stage #2: methyl iodide In acetonitrile Reflux; Darkness; | 99% |
chlorpromazine hydrochloride
Conditions | Yield |
---|---|
With potassium thioacyanate In water Rate constant; Ambient temperature; with different oxidizing agents, salt concentration, and various pH range; | 97% |
chlorpromazine hydrochloride
2-chloro-10-(3-dimethylaminopropyl)phenothiazine 5-oxide hydrochloride
Conditions | Yield |
---|---|
With dihydrogen peroxide In ethanol a) RT, overnight, b) reflux, 2 h; | 95.5% |
With hydrogenchloride; potassium metaperiodate In water Ambient temperature; | |
With n-C4F9; perfluoro-cis-2,3-dialkyloxaziridine; n-C3F7 In various solvent(s) at -40℃; for 0.5h; Yield given; |
ethyl bromide
chlorpromazine hydrochloride
3-(2-chloro-10H-phenothiazin-10-yl)-N-ethyl-N,N-dimethylpropan-1-aminium bromide
Conditions | Yield |
---|---|
Stage #1: chlorpromazine hydrochloride With sodium hydroxide In diethyl ether Stage #2: ethyl bromide In acetonitrile Reflux; Darkness; | 93% |
The IUPAC name of Chloropromazine hydrochloride is 3-(2-chlorophenothiazin-10-yl)-N,N-dimethylpropan-1-amine hydrochloride. With the CAS registry number 69-09-0, it is also named as 10-(3-Dimethylaminopropyl)-2-chlorophenothiazine monohydrochloride; Aminazin monohydrochloride; Fenactil monohydrochloride; Lomazine; Megaphen hydrochloride; Plegomazin; Tranzine; Phenothiazine, 2-chloro-10-(3-(dimethylamino)propyl)-, monohydrochloride. This product belongs to intermediates & fine chemicals and pharmaceuticals.
The Chloropromazine hydrochloride is white or creamy-white odorless crystalline powder with very bitter taste. It can be used as an Antiemetic and Antipsychotic. And it may decompose on exposure to air and light. In addition, it is incompatible in aqueous solution with sodium salts of barbiturates and other alkaline solutions. Solutions may be stabilized by addition of antioxidants and storing under nitrogen.
This chemical is toxic if swallowed and inhalation. After contact with skin, wash immediately with plenty of soap-suds. If you want to contact this product, you must wear suitable protective clothing and gloves. In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
The other characteristics of this product can be summarized as: (1)ACD/LogP: 5.20; (2)# of Rule of 5 Violations: 1; (3)ACD/LogD (pH 5.5): 2.17; (4)ACD/LogD (pH 7.4): 3.26; (5)ACD/BCF (pH 5.5): 4.93; (6)ACD/BCF (pH 7.4): 60.69; (7)ACD/KOC (pH 5.5): 15; (8)ACD/KOC (pH 7.4): 184.58; (9)#H bond acceptors: 2; (10)#H bond donors: 0; (11)#Freely Rotating Bonds: 4; (12)Enthalpy of Vaporization: 70.89 kJ/mol; (13)Vapour Pressure: 2.72E-08 mmHg at 25°C; (14)Rotatable Bond Count: 4; (15)Exact Mass: 354.072425; (16)MonoIsotopic Mass: 354.072425; (17)Topological Polar Surface Area: 31.8; (18)Heavy Atom Count: 22 ; (19)Complexity: 339.
People can use the following data to convert to the molecule structure. SMILES: Cl.Clc2cc1N(c3c(Sc1cc2)cccc3)CCCN(C)C; InChI: InChI=1/C17H19ClN2S.ClH/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20;/h3-4,6-9,12H,5,10-11H2,1-2H3;1H.
The following is the toxicity data which has been tested.
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
chicken | LD50 | intraperitoneal | 160mg/kg (160mg/kg) | Toxicology and Applied Pharmacology. Vol. 2, Pg. 558, 1960. | |
chicken | LD50 | intravenous | 28mg/kg (28mg/kg) | Toxicology and Applied Pharmacology. Vol. 2, Pg. 558, 1960. | |
guinea pig | LD50 | intraperitoneal | 109mg/kg (109mg/kg) | Pharmazie. Vol. 38, Pg. 749, 1983. | |
guinea pig | LD50 | subcutaneous | 420mg/kg (420mg/kg) | Archives Internationales de Pharmacodynamie et de Therapie. Vol. 137, Pg. 375, 1962. | |
man | TDLo | intravenous | 1786ug/kg/2D- (1.786mg/kg) | BEHAVIORAL: IRRITABILITY LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION SKIN AND APPENDAGES (SKIN): SWEATING: OTHER | Biological Psychiatry. Vol. 18, Pg. 1441, 1983. |
man | TDLo | oral | 6071ug/kg (6.071mg/kg) | Israel Journal of Medical Sciences. Vol. 5, Pg. 1254, 1969. | |
man | TDLo | oral | 18mg/kg (18mg/kg) | Israel Journal of Medical Sciences. Vol. 5, Pg. 1254, 1969. | |
monkey | LDLo | oral | > 30mg/kg (30mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: REGIDITY BEHAVIORAL: MUSCLE WEAKNESS | Archives Internationales de Pharmacodynamie et de Therapie. Vol. 122, Pg. 129, 1959. |
mouse | LC50 | inhalation | 40mg/m3/2H (40mg/m3) | "Prehled Prumyslove Toxikologie; Organicke Latky," Marhold, J., Prague, Czechoslovakia, Avicenum, 1986Vol. -, Pg. 1106, 1986. | |
mouse | LD50 | intraperitoneal | 92200ug/kg (92.2mg/kg) | Toxicology and Applied Pharmacology. Vol. 2, Pg. 558, 1960. | |
mouse | LD50 | intravenous | 20mg/kg (20mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 21, Pg. 808, 1971. | |
mouse | LD50 | oral | 135mg/kg (135mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: REGIDITY BEHAVIORAL: ALTERATION OF CLASSICAL CONDITIONING | Chemical and Pharmaceutical Bulletin. Vol. 24, Pg. 1179, 1976. |
mouse | LD50 | subcutaneous | 420mg/kg (420mg/kg) | British Journal of Pharmacology and Chemotherapy. Vol. 22, Pg. 301, 1964. | |
rabbit | LD50 | intravenous | 5mg/kg (5mg/kg) | "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 15, 1972. | |
rat | LC50 | inhalation | 40mg/m3/2H (40mg/m3) | "Prehled Prumyslove Toxikologie; Organicke Latky," Marhold, J., Prague, Czechoslovakia, Avicenum, 1986Vol. -, Pg. 1106, 1986. | |
rat | LD50 | intraperitoneal | 62mg/kg (62mg/kg) | Psychopharmacologia Vol. 12, Pg. 142, 1968. | |
rat | LD50 | intravenous | 25mg/kg (25mg/kg) | Fortschritte der Arzneimittelforschung. Progress in Drug Research. Vol. 5, Pg. 269, 1963. | |
rat | LD50 | oral | 145mg/kg (145mg/kg) | Journal of Pharmacology and Experimental Therapeutics. Vol. 148, Pg. 151, 1965. | |
rat | LD50 | unreported | 90mg/kg (90mg/kg) | "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 15, 1972. | |
women | TDLo | intravenous | 822ug/kg (0.822mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: EXCITEMENT CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP | Annals of Emergency Medicine. Vol. 17, Pg. 380, 1988. |
women | TDLo | oral | 6mg/kg (6mg/kg) | BEHAVIORAL: ANOREXIA (HUMAN GASTROINTESTINAL: OTHER CHANGES | Postgraduate Medical Journal. Vol. 60, Pg. 564, 1984. |
women | TDLo | oral | 35gm/kg/16Y-I (35000mg/kg) | BEHAVIORAL: REGIDITY CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION | Biological Psychiatry. Vol. 18, Pg. 1441, 1983. |